Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Abbott Acquires Global Rights to Biologic Pain Killer from PanGenetics
December 7, 2009
- Otsuka Withdraws Application for Abilify for Major Depression in Europe
December 7, 2009
- Price Maintenance System Essential to Promote Drug Industry: Mr Nagayama
December 7, 2009
- Sanofi-aventis, Regeneron Expand Strategic Antibody Collaboration
December 7, 2009
- Tsumura to File NDA for Daikenchuto in US in 2016
December 7, 2009
- Alfresa Pharma to Expand Contract Manufacturing Business
December 7, 2009
- US GLs Recommend Effient for ACS Patients Following PCI
December 7, 2009
- Pharma Industry to Become a Major Foreign Cashcow: Dr Sakurai of DPJ
December 7, 2009
- Biosimilar of EPO Recommended for Approval
December 7, 2009
- Market Price Survey Finds Mean Yakkasa of 8.4%
December 7, 2009
- Larger Differences in Prices Necessary between Original Drugs and Generics
December 7, 2009
- Japan's 1st GLP-1 Analogue Victoza Recommended for Approval
December 7, 2009
- Amgen to File NDA for AMG531 in Early 2010
December 7, 2009
- Afinitor, Abraxan Recommended for Approval
December 7, 2009
- Janssen Signs Clinical Research Aid Agreement with Keio Univ.
December 7, 2009
- Chuikyo to Decide on Industry Proposed Drug Pricing System Reform by Year-End
December 7, 2009
- Subanalysis Shows Greater Efficacy for Ticagrelor over Clopidogrel: AZ
December 7, 2009
- Cut Total Medical Fees by 3%: MOF
December 7, 2009
- Roche's GLYT-1 Inhibitor Improves Negative Symptoms of Schizophrenia
December 7, 2009
- Over 100 DPJ Legislators Get Together Calling for Increases in Medical Fees
December 7, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…